What Market Engineering Is Determines Whether Medtech Founders Build a Category or Just Compete

Market engineering is the discipline of deliberately designing, defining, and leading a market instead of waiting for one to form. For medtech founders, it breaks into four sequenced parts: category design, messaging, narrative, and go-to-market, always in that order.

It replaces the default move of hiring more sales reps with the earlier work of building a category buyers can recognize and choose.

Key Takeaways

• Market engineering breaks into four sequenced disciplines: category design, messaging, narrative, and go-to-market, in that order.
• Most medtech companies only execute the go-to-market piece and skip the category work that makes go-to-market effective.
• FDA clearance and clinical validation are not the same as market demand. A market has to be built, not just launched into.
• The starting point of market engineering is a minimum viable category, defined years before the first commercial hire.
• Bruce Cleveland coined "market engineering" to describe category definition, narrative, messaging, and positioning done well enough to separate winners from the rest.
• Real traction shows up as language adoption. Clinicians and buyers start using the category's own vocabulary before revenue becomes repeatable.

Watch the full episode on YouTube

What Market Engineering Requires Before the First Sales Hire

Market engineering is a formula founders can run step by step. On a recent episode about how market engineering helps medtech startups raise capital, I broke it down into four parts that have to happen in order: category design, messaging, narrative, and go-to-market.

Most medtech companies only do the fourth part, and they do not do it particularly well. Hiring more sales reps feels productive because it's tangible.

Money goes in, activity comes out, and a dashboard fills up. Category work is harder to point to, so founders skip straight to the part that looks like progress.

But you cannot outsell a misdefined market. A founder who has not done the category design, messaging, and narrative work is asking a sales team to close deals in a category that does not exist yet in the buyer's head.

So the reps burn through the pipeline faster, cycles get longer, and results stay inconsistent no matter how good the individual sellers are.

Minimum Viable Category Is Where Market Engineering Starts

Before product-market fit, before scaling, medtech founders need a minimum viable category. The category defines how the product gets evaluated. Without it, procurement and physician committees fall back on whatever category already exists, usually the one your biggest competitor already owns.

Founders who define the category first give buyers a new evaluation frame. Founders who skip it get evaluated on someone else's terms, in someone else's category, against someone else's incumbents.

Why Clinical Validation Is Not the Same as Market Demand

Clinical validation proves a device works. It does not prove a market wants it, and founders who confuse the two burn a funding round finding that out. This is the single most common misread among cleared medtech companies I talk to.

Most medtech companies do not fail because the product does not work. On an episode about VC discipline in early medtech strategy, I laid out why: they fail because the market never really forms around them.

Clinical validation is not adoption. FDA clearance is not demand. Innovation alone does not create a category.

The founders who avoid that trap do something specific. They engineer markets and craft narratives before they need to. They define a category, shape a belief among the buyers who matter, and build toward conditions where adoption feels inevitable rather than hoped for.

That is a different sequence than the one most founders default to. Clearance lands, the board wants commercial velocity, and the fastest visible lever is headcount.

But the founders who compound instead of stall usually spent the months before clearance on category and narrative, not just on the regulatory submission.

How Market-Product Fit Replaces the Old Product-Market Fit Model

Founders should stop optimizing for product-market fit and start optimizing for market-product fit. The order matters because it changes what a founder does first.

Define who the market is for. Then engineer the product's evaluation criteria around that market, instead of building the product and hoping a market discovers it.

On an episode I recorded about how mini strategics are winning $100B in exits, I made the sequencing case directly.

Founders should define who they are building for from day one, because that early definition is what lets validation, messaging, and valuation align instead of drifting apart.

Pricing and reimbursement economics belong in that same early window. Pricing is not only a revenue lever.

It signals market maturity to an acquirer, and it eliminates friction at the exact moment a strategic is deciding whether to underwrite your category or wait for someone else to define it.

Acquirers are not buying clinically valid technology on its own anymore. That is table stakes.

What they pay for is narrative clarity and momentum inside a category you already defined. Category design outcompetes on its own. Market engineering, done as a full sequence, outcompetes further.

How Do Founders Know When Market Engineering Is Working

The first real signal of market engineering working is language adoption. Traction starts when the people in your market begin describing the problem the way you frame it, before revenue tells you anything.

Founders often ask why early revenue does not count as traction on its own. Revenue can be episodic.

A strong launch and a few early adopters do not prove the sales process is repeatable, and they do not prove anyone besides the founder can run it. The real test is whether someone else in the company can replicate the sale, consistently and predictably.

Bruce Cleveland coined the term "market engineering" in his book on the subject, and he ties it to a specific bundle of work: thought leadership, category definition or redefinition, narrative, messaging, and positioning done together.

In his experience advising startups on exactly this, that bundle is what separates the companies that win from the companies with equally strong products that stay stuck.

When that bundle is working, sales cycles shorten, the need for buyer education drops, and demand starts to pull rather than push.

That is the shift from a founder-led, one-deal-at-a-time process to a category that sells itself faster with every quarter. For the full breakdown of the four disciplines in practice, see the 5 pillars of market engineering.

What This Means for Medtech Founders

In my experience working with medtech founders, market engineering gets treated as a marketing department problem when it is a sequencing problem the founder owns. The category design and narrative work has to happen before the go-to-market motion, not alongside it and never after.

If you are pre-clearance, the work to start now is category definition and the surgeon or buyer relationships that will validate it.

If you are post-clearance and stalling, look first at whether the category is defined clearly enough for your reps to sell against, before you add headcount. Most stalled commercial teams I see are not talent problems. They are category problems wearing a talent costume.

I would also push founders to separate clinical validation from market demand explicitly, in the boardroom and in the fundraising deck.

Investors have heard "we have clearance and traction" enough times that the phrase alone does not move them anymore. What moves them is evidence that the market has started using your language before you asked it to.

Read more on how this shows up in practice in the medtech go-to-market strategy framework and in what traction in business requires before a company can call it real.

Frequently Asked Questions

What is market engineering in medtech?

Market engineering is the discipline of deliberately designing, defining, and leading a market rather than waiting for one to form. It breaks into four sequenced parts: category design, messaging, narrative, and go-to-market. Medtech founders use it to build demand before scaling a sales team against a category buyers do not yet recognize.

How is market engineering different from marketing?

Marketing typically means campaigns, channels, and demand capture inside a category that already exists. Market engineering happens earlier. It defines the category itself, shapes the narrative buyers use to evaluate it, and only then moves into the messaging and go-to-market work that marketing usually owns.

What are the four parts of market engineering?

The four sequenced parts are category design, messaging, narrative, and go-to-market, always in that order. Category design comes first because it sets the evaluation frame everything else depends on. Skipping ahead to go-to-market without the earlier three parts is the most common founder mistake.

Who coined the term market engineering?

Bruce Cleveland coined "market engineering" in his book on the subject, defining it as the combination of thought leadership, category definition, narrative, messaging, and positioning that separates category winners from companies with comparable products that stay stuck.

Where to Go From Here

If you're doing this yourself. Start with the 5 pillars of market engineering to see the full framework applied, and listen to The State of MedTech for the founder interviews this post draws from.

If you want it engineered with you. MarketCraft takes on a small number of medtech teams each quarter, starting with The Market Engineering Audit. It maps where your category, narrative, and go-to-market sequence is out of order before you spend another quarter on the wrong one first.

Listen to the Full Episode

The full conversation on how market engineering helps medtech startups raise capital is available on The State of MedTech. Watch on YouTube. Subscribe wherever you listen to podcasts.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, the number one podcast in the medtech industry. He works with medtech founders and commercial leaders on market engineering, commercialization strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.